rheumatoid arthritis – current and future players · executive summary sales of rheumatoid...

REFERENCE CODE GDHC1041FPR | PUBLICAT ION DATE DECEMBER 2014

RHEUMATOID ARTHRITIS – CURRENT AND FUTURE PLAYERS

Rheumatoid Arthritis – Current and Future Players 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.


Executive Summary

Sales of Rheumatoid Arthritis Market

The Rheumatoid Arthritis (RA) market in the 10MM

(US, France, Italy, Germany, Spain, UK, Australia,

China, and India) is expected to grow at a

Compound Annual Growth Rate (CAGR) of 2.1%

during the forecast period, from 2013 sales of

$15.6 billion to sales of $19.3 billion in 2023.

The major drivers of growth in the global RA

market during the forecast period are:

An increase in the prevalent cases of RA in all

the markets, in part, due to an aging population

The anticipated introduction of interleukin (IL)-6

inhibitors (Sanofi/Regeneron’s sarilumab,

Johnson & Johnson/GlaxoSmithKline’s

[J&J/GSK’s] sirukumab, Alder’s clazakizumab),

novel biologics (Novartis’ Cosentyx,

AstraZeneca/MedImmune’s mavrilimumab,

AbbVie/Biotest’s tregalizumab, and

Amgen/Daiichi Sankyo’s denosumab), small

molecules (four janus kinase [JAK] inhibitors:

Eli Lilly/Incyte’s baricitinib, Astellas’ peficitinib,

Vertex’s decernotinib, AbbVie/Galapagos’

filgotinib; and one c-Kit inhibitor: AB Science’s

masitinib), which will expand options to treat

RA patients and contribute to overall market

growth

The early diagnosis and treatment of patients

with RA to limit disease progression

The market entry of biosimilars, which will

make RA treatments more accessible

The major barriers to the growth of the global RA

market during the forecast period are:

The high cost of biologics, which will limit their

uptake, especially in cost-conscious markets

that are facing austerity measures

The lack of regulatory guidance on biosimilars

The market entry of biosimilars, which will

provide a less expensive alternative and will

challenge the established brands

The figure below shows the sales for RA in the

10MM by region during the forecast period.

Sales for RA by Region, 2013–2023

67%

19%

6%3%

2% 3%

US

5EU

Japan

Australia

China

India

65%

19%

6%3%

3% 4%

2013Total: $15.6bn

2023Total: $19.3bn

Source: GlobalData



Executive Summary

The RA Market is Dominated by Big Pharma and Biologics

J&J, AbbVie and Pfizer have been the dominant

players in the RA market since the introduction of

Remicade (1998), Humira (2002) and Enbrel

(1998), first three TNF inhibitors approved by the

FDA, respectively. Together, the first two biologic

brands represented the top two best-selling drugs

across the entire pharmaceutical industry in 2013,

due to their high price and additional approvals for

other autoimmune indications

The RA market has become increasingly

competitive, with both SC and IV therapies being

available, the approval of an oral therapy (with

others pending), and the entry of biosimilars

looming on the horizon. AbbVie’s leading role is

solely attributable to Humira, which became the

top-selling drug in the world in 2013. Patents are

expected to expire in 2016 (US) and 2018 (5EU),

exposing sales of the product to biosimilar

competition. GlobalData predicts that biosimilars

will launch in the US in 2017 and in the 5EU in

2018, with sales for Humira beginning to dip in

2017. Abbvie has two other products to cushion its

sales losses with GLPG0634 and tregalizumab in

partnership with Galapagoees and Biotest

respectively.

J&J, the patent for Remicade will expire between

2014 and 2015 (5EU with the specific date being

dependent on the country), and 2018 (US).

However, Simponi, J&J’s second-generation TNF

inhibitor, was launched in 2009, and is patent-

protected until after the forecast period, with its

patent expiring in 2024 in both the US and 5EU.

In 2012, Pfizer exited its agreement with Amgen for

the US marketing of Enbrel, retaining its ex-US

marketing rights to the drug. 2015 will see the

arrival of biosimilars, which will curtail Enbrel’s

revenue in markets outside the US. Pfizer’s hopes

for RA rely in Xeljanz, which was approved 2012

(US), and 2013 (Japan). However, the drug was

given a negative opinion twice over the course of

three months in 2013 (in April and July 2013) by

the CHMP in the EU, and the brand posted less

than impressive sales in 2013 at $114m (Pfizer,

2014a). As such, Pfizer’s continued success in the

RA market will hinge on overcoming hurdles in

order to gain approval for Xeljanz in the 5EU and in

additional non-7MM markets

New Entrants and their Portfolios

With the leading players in the RA market facing

patent expiries, there will be room for the entry of

new players by the end of the forecast period. Key

candidates include GSK and Eli Lilly, which have

been focusing on partnerships to segue into the

immune-inflammatory disease fields. GSK has

three novel entities in the early to late stages of

development, two of which are the result of

collaborative efforts, the first being with J&J for



Executive Summary

sirukumab, an IL-6 inhibitor (forecasted launch:

2018). The other is with MorphoSys for a novel

biologic, GSK-3196165, that targets GM-CSF. Eli

Lilly’s prospects dimmed in 2013 with the failure of

its Phase III pipeline candidate, tabalumab, an anti-

B-cell activating factor (BAFF) mAb, due to a lack

of efficacy. However, the company still has

baricitinib, an oral JAK1/2 inhibitor, in the late

stage of clinical development

Partnerships at Early Stage of Development

The major players in the RA market have extensive

portfolios, and may enter into Phase I buyouts and

partnerships at very early stages. It is especially

common for these companies to form an early

partnership for development in the Japanese

market: for example, AstraZeneca/MedImmune’s

partnership with Daiichi Sankyo on the Phase I

biologic known as AMP-110. Fragmented and

competitive landscape, favors these collaborations

to overcome both R&D and commercial barriers.

For example, Regeneron has partnered with Sanofi

for the Phase III IL-6 inhibitor, sarilumab. It is also

common for Big Pharma to team up together and

leverage their positions in the global markets, as is

the case with sirukumab, an IL-6 inhibitor backed

by both J&J and GSK.

Premium Pricing for Biologics

While the development of biologics is both a

difficult and expensive endeavor, pharmaceutical

companies have used it to their advantage by

pricing these drugs upwards of $30,000 per year,

and making sure, a small patient share often

translates into big earnings in crowded markets.

Pfizer used this pricing strategy to its advantage

when Xeljanz (tofacitinib) launched in the US in

2012 and in Japan in 2013. At that time, there were

no oral disease-modifying anti-rheumatic drugs

(DMARDs) on the market to compete with the

biologics, so Pfizer priced its small molecule close

to that of a biologic agent.

Indication Expansion

Since the pathophysiology of RA overlaps with that

of other inflammatory diseases, most RA drugs will

undergo label expansions into additional

indications, such as ankylosing spondylitis,

psoriasis, psoriatic arthritis, systemic lupus

erythematosus, and ulcerative colitis. However, the

major brands for RA will soon face patent

expiration, and biosimilars will be available in all 10

markets covered in this report by the conclusion of

the forecast period in 2023. Biosimilars alone are

forecast at $4.6 billion for the 2023 RA market, with

adalimumab biosimilars accounting for nearly half

that number at $2 billion.



Executive Summary

Meanwhile, a strategy being utilized by Roche,

another key player in the RA market, is to

strengthen its brand, and the company is currently

running several post-marketing trials for Actemra

(tocilizumab) to establish the drug’s position within

the treatment paradigm. Several Big Pharma

companies, such as Pfizer and Amgen, have

realized the potential of biosimilars in the RA

market and have launched programs to develop

biosimilars of their own.

The figure below provides an analysis of the

company portfolio gap in RA during the forecast

period.

Company Portfolio Gap Analysis in RA, 2013–2023

Strength of Pipeline

Low High

Hig

hLo

w

Stre

ngth

of M

arke

ted

Pro

duct

s

Current and Future Players

Future Players

Current Players

Source: GlobalData

What Do Physicians Think?

The RA market is very competitive, and the new

entrants are expected to be met with some

resistance and experience slow uptake, as the

market is currently dominated by the anti-TNFs,

and rheumatologists feel comfortable with the long-

term safety and efficacy of this class of drugs.

“We at least have a reasonably good handle on

what the long-term or relatively long-term safety

profile of [the] anti-TNFs is. They’re not perfect, but

at least we know what the issues are, and there

are concerns, I think, with the [the] long-term safety

profiles of some of the new agents that have come

through. And so, given that we rheumatologists

feel more comfortable with the anti-TNFs…, we

know what to look out for. Then, for any new

players…, it can be difficult to compete because

the concern is always, well, maybe the new drug

might have long-term side effects, and so we better

use the ones that we’ve got more — [that] we’re

more familiar with.”

[EU] KOL



Executive Summary

“Unless we can upfront identify a group in whom

it’s [a pipeline agent] going to be effective…, [or]

unless it’s marketed at a significantly lower cost

than its competitors, what will happen is that the

[new] drug will be used fourth or fifth line, etcetera.

Because if it costs the same as a currently

available biologic, the currently available biologics

have got a stronger history, [a] longer history of

maybe safety and efficacy data, [so] why would

you choose to use the new one unless you’d

actually tried and failed [with] the old ones? The

problem with that, of course, for the new ones, is

that they end up being tried on often the most

difficult rheumatoid [arthritis] patients, and so, often

they don’t work.”

[EU] KOL

One of the greatest challenges with the

introduction of new biologics in the RA market will

be to target these drugs to the right patients. Many

rheumatologists believe that the future of RA is in

individualized medicine, where biomarkers

determine the best course of action for each

patient.

“I think the patients find the whole process [of

finding an effective therapy to be] very difficult.

They often lose faith in our approach to treat their

disease well. It may have an impact on their

adherence to medication in the future. We kind of

keep dropping and changing between one thing

and another thing. How do they know that the fifth

thing is going to work when the first four haven’t?

Actually, adherence to drugs is a big issue in

people with long-term conditions [such as RA], and

the fact that it can take us a long time to find

something that works, I think, is a big issue in the

context of that for the patients as well.”

[UK] KOL

“I think it will be very difficult for rheumatologists to

manage this huge number of different drugs that

are available without us having some kind of

strategy for establishing which groups of patients

each particular drug would be most effective in,

and so that kind of takes us down to [the]

personalized medicine route, and I think that’s

what companies need to be looking at as they’re

developing these new agents….We need to work

out who to treat with what — who to treat with what

drug, based on identifying biomarkers that predict

[the patient’s] response, which could be ones that

you measure in the blood or [the] ones that you

measure from the joint, but I think that will have to

be the direction of travel.”

[EU] KOL



Executive Summary

One of the greatest unmet needs in RA is the

affordability of drugs, as the biologics cost upwards

of $30,000 per year in the US. Biosimilars are

expected to launch over the forecast period from

2013–2023 in all 10 markets covered in this report,

changing the market dynamics and offering a less

expensive alternative to the branded biologics.

“If a biosimilar is only half as expensive [as the

originator brand] — which it’s probably not, [as

that’s] probably overly optimistic — it’s still way out

of the reach of most patients if they have [health

insurance] coverage problems. Yes, it will help the

overall system, but [it will] probably not help the

individual patient very much. [I would prescribe

biosimilars when they are available] sure,

absolutely….You would potentially replace the

innovative product with a biosimilar whenever you

have that option. The only reason you do that,

obviously, is cost. In most cases, it’s not going to

be my decision; it’s going to be the decision of

whoever is paying for it….It will be helpful, but it’s

not going to be a big game-changer….Two thirds

of [what is already] a heck of a lot of money is still

almost a heck of a lot of money, and most people

don’t have that.”

[US] KOL


Table of Contents


1 Table of Contents

1 Table of Contents ....................................................................................................................... 8

1.1 List of Tables .................................................................................................................... 10

1.2 List of Figures ................................................................................................................... 11

2 Introduction ............................................................................................................................... 12

2.1 Catalyst ............................................................................................................................. 12

2.2 Related Reports ................................................................................................................ 13

2.3 Upcoming Related Reports ............................................................................................... 16

3 Market Outlook ......................................................................................................................... 17

3.1 Global Markets .................................................................................................................. 17

3.1.1 Forecast ........................................................................................................................ 17

3.1.2 Drivers and Barriers – Global Issues ............................................................................. 22

4 Current and Future Players ....................................................................................................... 25

4.1 Trends in Corporate Strategy ............................................................................................ 28

4.2 Company Profiles .............................................................................................................. 29

4.2.1 AbbVie .......................................................................................................................... 29

4.2.2 Pfizer ............................................................................................................................. 31

4.2.3 Amgen........................................................................................................................... 34

4.2.4 Johnson & Johnson ....................................................................................................... 37

4.2.5 Eli Lilly ........................................................................................................................... 39

4.2.6 Bristol-Myers Squibb ..................................................................................................... 41

4.2.7 UCB .............................................................................................................................. 43


Table of Contents


4.2.8 Roche............................................................................................................................ 45

4.2.9 GlaxoSmithKline ............................................................................................................ 47

4.2.10 Novartis ......................................................................................................................... 49

4.2.11 Sanofi ............................................................................................................................ 51

4.2.12 AstraZeneca- MedImmune ............................................................................................ 53

4.2.13 Astellas ......................................................................................................................... 55

4.2.14 Vertex............................................................................................................................ 57

4.2.15 Daiichi Sankyo .............................................................................................................. 59

5 Appendix................................................................................................................................... 61

5.1 Bibliography ...................................................................................................................... 61

5.2 Abbreviations .................................................................................................................... 67

5.3 Methodology ..................................................................................................................... 70

5.4 Forecasting Methodology .................................................................................................. 70

5.4.1 Diagnosed RA Patients ................................................................................................. 70

5.4.2 Percentage of Drug-Treated Patients ............................................................................ 71

5.4.3 General Pricing Assumptions ........................................................................................ 71

5.4.4 Generic and Biosimilar Erosion ..................................................................................... 73

5.5 Primary Research – KOLs Interviewed for This Report ..................................................... 74

5.6 Primary Research – Prescriber Survey ............................................................................. 76

5.7 About the Authors ............................................................................................................. 77

5.7.1 Analyst .......................................................................................................................... 77

5.7.2 Reviewer ....................................................................................................................... 77

5.7.3 Therapy Area Director ................................................................................................... 78


Table of Contents


5.7.4 Global Head of Healthcare ............................................................................................ 78

5.8 About GlobalData .............................................................................................................. 79

5.9 Disclaimer ......................................................................................................................... 79

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for RA, 2013–2023 ......................................................................... 19

Table 2: Global RA Market – Drivers and Barriers, 2013–2023 .................................................................. 22

Table 3: Key Companies in the RA Market, 2014 ...................................................................................... 27

Table 4: AbbVie’s RA Portfolio Assessment, 2014..................................................................................... 30

Table 5: Pfizers’s RA Portfolio Assessment, 2014 ..................................................................................... 33

Table 6: Amgen’s RA Portfolio Assessment, 2014 ..................................................................................... 36

Table 7: J&J’s RA Portfolio Assessment, 2014 .......................................................................................... 38

Table 8: Eli Lilly’s RA Portfolio Assessment, 2014 ..................................................................................... 40

Table 9: BMS’ RA Portfolio Assessment, 2014 .......................................................................................... 42

Table 10: UCB’s RA Portfolio Assessment, 2014 ........................................................................................ 44

Table 11: Roche’s RA Portfolio Assessment, 2014 ...................................................................................... 46

Table 12: GSK’s RA Portfolio Assessment, 2014 ........................................................................................ 48

Table 13: Novartis’ RA Portfolio Assessment, 2014 ..................................................................................... 50

Table 14: Sanofi’s RA Portfolio Assessment, 2014 ...................................................................................... 52

Table 15: AstraZeneca -MedImmune’s RA Portfolio Assessment, 2014 ....................................................... 54

Table 16: Astellas’s RA Portfolio Assessment, 2014 .................................................................................... 56

Table 17: Vertex’s RA Portfolio Assessment, 2014 ...................................................................................... 58

Table 18: Daiichi Sankyo’s RA Portfolio Assessment, 2014 ......................................................................... 60

Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country .................................................. 76


Table of Contents


1.2 List of Figures

Figure 1: Global Sales for RA by Region, 2013–2023 ................................................................................. 21

Figure 2: Company Portfolio Gap Analysis in RA, 2013–2023..................................................................... 28

Figure 3: AbbVie SWOT Analysis in RA, 2013–2023 .................................................................................. 31

Figure 4: Pfizer SWOT Analysis in RA, 2013–2023 .................................................................................... 34

Figure 5: Amgen SWOT Analysis in RA, 2013–2023 .................................................................................. 36

Figure 6: J&J SWOT Analysis in RA, 2013–2023 ....................................................................................... 39

Figure 7: Eli Lilly SWOT Analysis in RA, 2013–2023 .................................................................................. 41

Figure 8: BMS SWOT Analysis in RA, 2013–2023 ...................................................................................... 43

Figure 9: UCB SWOT Analysis in RA, 2013–2023 ...................................................................................... 45

Figure 10: Roche SWOT Analysis in RA, 2013–2023 ................................................................................... 47

Figure 11: GSK SWOT Analysis in RA, 2013–2023 ...................................................................................... 49

Figure 12: Novartis SWOT Analysis in RA, 2013–2023................................................................................. 51

Figure 13: Sanofi SWOT Analysis in RA, 2013–2023 ................................................................................... 53

Figure 14: AstraZeneca/MedImmune SWOT Analysis in RA, 2013–2023 ..................................................... 55

Figure 15: Astellas SWOT Analysis in RA, 2013–2023 ................................................................................. 57

Figure 16: Vertex SWOT Analysis in RA, 2013–2023 ................................................................................... 59

Figure 17: Daiichi Sankyo SWOT Analysis in RA, 2013–2023 ...................................................................... 61



Introduction

2 Introduction

2.1 Catalyst

The Rheumatoid Arthritis (RA) market will grow over the 2013–2023 forecast period, driven by a

number of new product launches, such as:

Novel biologics

Anti-interleukin (IL)-6 biologics

Small molecules, including janus kinase (JAK) inhibitors

Other factors that will drive market expansion are growth in the emerging markets of China, India,

and Australia, where product launches extend product lifecycles. In addition, there will be an

increase in the prevalence of RA across the 10 major markets (10MM) covered in this report.

The loss of patent protection for the anti-tumor necrosis factor (TNF) marketed brands will allow for

the emergence of biosimilars, such as Celltrion’s Remsima (infliximab)/Hospira’s Inflectra

(infliximab), which is a Remicade biosimilar. The patent expiries begin in 2015 and 2016,

respectively, for the current market leaders:

J&J’s Remicade

AbbVie’s Humira

The catalysts and objectives for this report are to:

Determine the impact that biosimilars will have on the RA market

Assess the uptake of JAK inhibitors, including Pfizer’s Xeljanz (tofacitinib) and other pipeline

agents

Identify the unmet needs in the RA market

Determine the remaining opportunities in the RA market



Introduction

2.2 Related Reports

GlobalData (2014). PharmaPoint: Ulcerative Colitis – Global Drug Forecast and Market

Analysis to 2022, Event-Driven Update, September 2014, GDHC005EPIDR

GlobalData (2014). PharmaPoint: Crohn's Disease – Global Drug Forecast and Market

Analysis to 2022, January 2014, GDHC77PIDR

GlobalData (2014). PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market

Analysis to 2022, November 2013, GDHC66PIDR

GlobalData (2014). PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis –

Global Drug Forecast and Market Analysis to 2022, October 2013, GDHC65PIDR

GlobalData (2014). PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to

2022, May 2013, GDHC48PIDR

GlobalData (2014) PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast

And Market Analysis To 2023, December 2014, GDHC93PIDR

GlobalData (2014) Rheumatoid Arthritis – US Drug Forecast and Market Analysis to 2023,

December 2014, GDHC264CFR

GlobalData (2014) Rheumatoid Arthritis – 5EU Drug Forecast and Market Analysis to 2023,


GlobalData (2014) Rheumatoid Arthritis – Japan Drug Forecast and Market Analysis to 2023,


GlobalData (2014) Rheumatoid Arthritis – Australia Drug Forecast and Market Analysis to

2023, December 2014, GDHC267CFR

GlobalData (2014) Rheumatoid Arthritis – China Drug Forecast and Market Analysis to 2023,


GlobalData (2014) Rheumatoid Arthritis – India Drug Forecast and Market Analysis to 2023,


GlobalData. Enbrel (etanercept) (Rheumatoid Arthritis) – Forecast and Market Analysis to

2023, December 2014, GDHC492DFR



Introduction

GlobalData. Humira (adalimumab) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Remicade (infliximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Simponi (golimumab) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Cimzia (certolizumab pegol) (Rheumatoid Arthritis) – Forecast and Market

Analysis to 2023, December 2014, GDHC496DFR

GlobalData. Orencia (abatacept) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Actemra/RoActemra (tocilizumab) (Rheumatoid Arthritis) – Forecast and Market


GlobalData. Rituxan/MabThera (rituximab) (Rheumatoid Arthritis) – Forecast and Market


GlobalData. Inflectra/Remsima/Biosimilars (Rheumatoid Arthritis) – Forecast and Market


GlobalData. Xeljanz (tofacitinib) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Iguratimod/T-614 (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,

December 2014, GDHC502DFR

GlobalData. Methotrexate (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Sarilumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Sirukumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,




Introduction

GlobalData. Clazakizumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Cosentyx (secukinumab) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Tregalizumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Mavrilimumab (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Denosumab (Prolia) (Rheumatoid Arthritis) – Forecast and Market Analysis to


GlobalData. Baricitinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Peficitinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Decernotinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Filgotinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. Masitinib (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023,


GlobalData. RAVAX (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023, December

2014, GDHC516DFR



Introduction

2.3 Upcoming Related Reports

GlobalData (2015). Opportunity Analyzer: Ankylosing Spondylitis and Non-Radiographic Axial

Spondyloarthritis – Global Drug Forecast and Market Analysis to 2023, to be published in

March 2015

GlobalData (2015). PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market

Analysis to 2022, Event-Driven Update, to be published in January 2015

GlobalData (2015). PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis –

Global Drug Forecast and Market Analysis to 2022, Event-Driven Update, to be published in

January 2015

`


Appendix


5.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry.

GlobalData provides its clients with up-to-date information and analysis on the latest developments

in drug research, disease analysis, and clinical research and development. Our integrated business

intelligence solutions include a range of interactive online databases, analytical tools, reports, and

forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan,

Singapore, and Australia.

5.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any

form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior

permission of the publisher, GlobalData.

rheumatoid arthritis – current and future players · executive summary sales of rheumatoid...

Documents